The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public telehealth company.

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Hims & Hers (HIMS) stock took a steep dive ... Instead, the company will focus on weight-loss pills and a generic version of liraglutide — an older GLP-1 drug taken daily instead of weekly ...

But with GLP-1 sales vanishing, Hims is left banking on generic weight-loss pills and its core business in hair-loss and ED treatments. While that business is solid, it doesn't justify the lofty ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

The "Hims and Hers" commercial railed against the weight ... medication presented by researchers in Spain that shows significant potential for weight loss that comes in pill form. A new study finds ...

Hims & Hers expects its weight loss business to bring in $725 million ... ability to offer a "wide range of personalized treatments, supplements and medications and accelerate the expansion ...